NasdaqGS:ADPTLife Sciences
Does Adaptive Biotechnologies’ (ADPT) Convertible Raise and Split Plan Reveal a New Strategic Center of Gravity?
Earlier in June 2026, Adaptive Biotechnologies completed a US$300,000,000 zero-coupon, senior unsecured convertible notes offering due July 1, 2031, shortly after announcing plans to separate its Minimal Residual Disease and Immune Medicine businesses and evaluate alternatives for the Immune Medicine unit.
This combination of a planned business separation and fresh convertible funding highlights Adaptive’s effort to refine its business focus while bolstering financial flexibility for future...